Outcomes of Fungemia in Patients Receiving Extracorporeal Membrane Oxygenation

Melissa M Rosas; Michal J Sobieszczyk; Whittney Warren; Phillip Mason; Robert J Walter; Joseph E Marcus

doi:10.1093/ofid/ofac374

Outcomes of Fungemia in Patients Receiving Extracorporeal Membrane Oxygenation

Open Forum Infect Dis. 2022 Jul 25;9(8):ofac374. doi: 10.1093/ofid/ofac374. eCollection 2022 Aug.

Authors

Melissa M Rosas¹, Michal J Sobieszczyk¹, Whittney Warren¹, Phillip Mason², Robert J Walter¹, Joseph E Marcus³

Affiliations

¹ Pulmonary and Critical Care Division, Department of Medicine, Brooke Army Medical Center, Joint Base San Antonio, Texas, USA.
² Critical Care Division, Emergency Medicine, Brooke Army Medical Center, Joint Base San Antonio, Texas, USA.
³ Infectious Disease Division, Department of Medicine, Brooke Army Medical Center, Joint Base San Antonio, Texas, USA.

Abstract

There are limited data on the treatment of fungal infections complicating extracorporeal membrane oxygenation (ECMO). In 14 patients who developed fungal bloodstream infections on ECMO, 8 (57%) survived to discharge. Of the 5 patients completing treatment prior to decannulation, 2 (40%) developed recurrent fungal infections.

Keywords: COVID-19; extracorporeal membrane oxygenation; fungemia.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.